Cargando…

Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross‐sectional study

OBJECTIVES: The reported prevalence of chronic obstructive pulmonary disease (COPD) in people living with HIV (PLWHIV) varies widely. Our objective was to estimate the prevalence of airflow obstruction and COPD in unselected PLWHIV and identify characteristics that increase the risk of nonreversible...

Descripción completa

Detalles Bibliográficos
Autores principales: Costiniuk, CT, Nitulescu, R, Saneei, Z, Wasef, N, Salahuddin, S, Wasef, D, Young, J, de Castro, C, Routy, JP, Lebouché, B, Cox, J, Smith, BM, Ambroise, S, Pexos, C, Patel, M, Szabo, J, Haraoui, LP, de Pokomandy, A, Tsoukas, C, Falutz, J, LeBlanc, R, Giannakis, A, Frenette, C, Jenabian, MA, Bourbeau, J, Klein, MB
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590155/
https://www.ncbi.nlm.nih.gov/pubmed/30620136
http://dx.doi.org/10.1111/hiv.12699
_version_ 1783429496837242880
author Costiniuk, CT
Nitulescu, R
Saneei, Z
Wasef, N
Salahuddin, S
Wasef, D
Young, J
de Castro, C
Routy, JP
Lebouché, B
Cox, J
Smith, BM
Ambroise, S
Pexos, C
Patel, M
Szabo, J
Haraoui, LP
de Pokomandy, A
Tsoukas, C
Falutz, J
LeBlanc, R
Giannakis, A
Frenette, C
Jenabian, MA
Bourbeau, J
Klein, MB
author_facet Costiniuk, CT
Nitulescu, R
Saneei, Z
Wasef, N
Salahuddin, S
Wasef, D
Young, J
de Castro, C
Routy, JP
Lebouché, B
Cox, J
Smith, BM
Ambroise, S
Pexos, C
Patel, M
Szabo, J
Haraoui, LP
de Pokomandy, A
Tsoukas, C
Falutz, J
LeBlanc, R
Giannakis, A
Frenette, C
Jenabian, MA
Bourbeau, J
Klein, MB
author_sort Costiniuk, CT
collection PubMed
description OBJECTIVES: The reported prevalence of chronic obstructive pulmonary disease (COPD) in people living with HIV (PLWHIV) varies widely. Our objective was to estimate the prevalence of airflow obstruction and COPD in unselected PLWHIV and identify characteristics that increase the risk of nonreversible airflow obstruction in order to guide case finding strategies for COPD. METHODS: All adults attending the Chronic Viral Illness Service were invited to participate in the study, regardless of smoking status or history of known COPD/asthma. Individuals underwent spirometric testing both before and after use of a salbutamol bronchodilator. Airflow obstruction was defined as forced expiratory volume in 1 s (FEV (1))/forced vital capacity (FVC) < 0.7 post‐bronchodilation, whereas COPD was defined as FEV (1)/FVC < 0.7 post‐bronchodilation and Medical Research Council (MRC) score > 2. Multivariate logistic regression was used to evaluate risk factors associated with airflow obstruction, reported as adjusted odds ratios (aORs). RESULTS: Five hundred and three participants successfully completed spirometry testing. The median (Q1; Q3) age was 52 (44; 58) years. The median (Q1; Q3) CD4 count was 598 (438; 784) cells/μL and the median (Q1; Q3) nadir CD4 count was 224 (121; 351) cells/μL. There were 119 (24%) current smokers and 145 (29%) former smokers. Among those screened, 54 (11%) had airflow obstruction whereas three (1%) of the participants had COPD. Factors that were associated with airflow obstruction included a history of smoking [aOR 2.2; 95% confidence interval (CI) 1.1; 4.7], older age (aOR 1.6; 95% CI 1.2; 2.2), and lower CD4 count (aOR 0.8; 95% CI 0.7; 1.0). CONCLUSIONS: Airflow obstruction was relatively uncommon. Our findings suggest that PLWHIV who are ≥50 years old, smokers and those with nadir CD4 counts ≤ 200 cells/μL could be targeted to undergo spirometry to diagnose chronic airflow obstruction.
format Online
Article
Text
id pubmed-6590155
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65901552019-07-08 Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross‐sectional study Costiniuk, CT Nitulescu, R Saneei, Z Wasef, N Salahuddin, S Wasef, D Young, J de Castro, C Routy, JP Lebouché, B Cox, J Smith, BM Ambroise, S Pexos, C Patel, M Szabo, J Haraoui, LP de Pokomandy, A Tsoukas, C Falutz, J LeBlanc, R Giannakis, A Frenette, C Jenabian, MA Bourbeau, J Klein, MB HIV Med Original Research OBJECTIVES: The reported prevalence of chronic obstructive pulmonary disease (COPD) in people living with HIV (PLWHIV) varies widely. Our objective was to estimate the prevalence of airflow obstruction and COPD in unselected PLWHIV and identify characteristics that increase the risk of nonreversible airflow obstruction in order to guide case finding strategies for COPD. METHODS: All adults attending the Chronic Viral Illness Service were invited to participate in the study, regardless of smoking status or history of known COPD/asthma. Individuals underwent spirometric testing both before and after use of a salbutamol bronchodilator. Airflow obstruction was defined as forced expiratory volume in 1 s (FEV (1))/forced vital capacity (FVC) < 0.7 post‐bronchodilation, whereas COPD was defined as FEV (1)/FVC < 0.7 post‐bronchodilation and Medical Research Council (MRC) score > 2. Multivariate logistic regression was used to evaluate risk factors associated with airflow obstruction, reported as adjusted odds ratios (aORs). RESULTS: Five hundred and three participants successfully completed spirometry testing. The median (Q1; Q3) age was 52 (44; 58) years. The median (Q1; Q3) CD4 count was 598 (438; 784) cells/μL and the median (Q1; Q3) nadir CD4 count was 224 (121; 351) cells/μL. There were 119 (24%) current smokers and 145 (29%) former smokers. Among those screened, 54 (11%) had airflow obstruction whereas three (1%) of the participants had COPD. Factors that were associated with airflow obstruction included a history of smoking [aOR 2.2; 95% confidence interval (CI) 1.1; 4.7], older age (aOR 1.6; 95% CI 1.2; 2.2), and lower CD4 count (aOR 0.8; 95% CI 0.7; 1.0). CONCLUSIONS: Airflow obstruction was relatively uncommon. Our findings suggest that PLWHIV who are ≥50 years old, smokers and those with nadir CD4 counts ≤ 200 cells/μL could be targeted to undergo spirometry to diagnose chronic airflow obstruction. John Wiley and Sons Inc. 2019-01-08 2019-03 /pmc/articles/PMC6590155/ /pubmed/30620136 http://dx.doi.org/10.1111/hiv.12699 Text en © 2019 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Costiniuk, CT
Nitulescu, R
Saneei, Z
Wasef, N
Salahuddin, S
Wasef, D
Young, J
de Castro, C
Routy, JP
Lebouché, B
Cox, J
Smith, BM
Ambroise, S
Pexos, C
Patel, M
Szabo, J
Haraoui, LP
de Pokomandy, A
Tsoukas, C
Falutz, J
LeBlanc, R
Giannakis, A
Frenette, C
Jenabian, MA
Bourbeau, J
Klein, MB
Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross‐sectional study
title Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross‐sectional study
title_full Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross‐sectional study
title_fullStr Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross‐sectional study
title_full_unstemmed Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross‐sectional study
title_short Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross‐sectional study
title_sort prevalence and predictors of airflow obstruction in an hiv tertiary care clinic in montreal, canada: a cross‐sectional study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590155/
https://www.ncbi.nlm.nih.gov/pubmed/30620136
http://dx.doi.org/10.1111/hiv.12699
work_keys_str_mv AT costiniukct prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT nitulescur prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT saneeiz prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT wasefn prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT salahuddins prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT wasefd prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT youngj prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT decastroc prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT routyjp prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT leboucheb prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT coxj prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT smithbm prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT ambroises prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT pexosc prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT patelm prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT szaboj prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT haraouilp prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT depokomandya prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT tsoukasc prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT falutzj prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT leblancr prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT giannakisa prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT frenettec prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT jenabianma prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT bourbeauj prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy
AT kleinmb prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy